{"id":"W2152106583","doi":"10.1111/j.1610-0387.2006.06111.x","title":"CLinical Experience Acquired with Raptiva<sup>®</sup> (CLEAR) trial in patients with moderate‐to‐severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo‐controlled trial","year":2006,"lang":"en","type":"article","venue":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Efalizumab; Medicine; Psoriasis Area and Severity Index; Placebo; Clinical trial; Open label; Plaque psoriasis; Psoriasis; Randomized controlled trial; Internal medicine; Adverse effect; Refractory (planetary science); Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009172754,0.0009641847,0.002138825,0.000727669,0.0003487849,0.0002325276,0.0008720838,0.0008852084,0.0002602073],"category_scores_gemma":[0.0002217983,0.0006463721,0.0003772968,0.0004334382,0.000278685,0.001049658,0.0001165263,0.0007341878,0.0001240305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003114241,"about_ca_system_score_gemma":0.0004434743,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003664452,"about_ca_topic_score_gemma":0.000357658,"domain_scores_codex":[0.9921743,0.002304191,0.002667864,0.00136141,0.0003839073,0.001108313],"domain_scores_gemma":[0.996636,0.0009523134,0.001017964,0.0008185282,0.0003141576,0.0002610365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9461401,0.01035167,0.03245037,0.00000257327,0.001413527,0.0005483859,0.003251341,0.001640065,0.0001442385,0.00001450863,0.0005330254,0.003510211],"study_design_scores_gemma":[0.9727601,0.009003925,0.0123209,0.0001386199,0.0005004935,0.0001479601,0.001231912,0.0005306567,0.00109201,0.0000734746,0.001353316,0.0008466374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921771,0.0004971696,0.0002370882,0.0004715993,0.001054946,0.00487278,0.0001935956,0.0001054965,0.0003902183],"genre_scores_gemma":[0.9950937,0.0002033637,0.001710374,0.0001764209,0.0004804934,0.0009325282,0.0007593583,0.00007938488,0.0005643904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02662001,"threshold_uncertainty_score":0.9995987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02832144192445271,"score_gpt":0.3036950582499319,"score_spread":0.2753736163254792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}